Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
GMLP / Golar LNG Partners LP FORM 6-K (Current Report of Foreign Issuer)

2018-07-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
GMLP

0
The Hidden Jewel Behind This 15% Yield

2018-07-14 seekingalpha
Golar LNG Partners LP (GMLP), an LNG shipping company, has had several challenging quarters due to its vessels coming off contracts and being layed up/drydocked for mandatory surveys.
GMLP GLNG

22
Teekay Continues To Transition - What's The Timing?

2018-07-13 seekingalpha
Teekay Corporation has been one of my largest personal holdings, largely based upon their control of Teekay LNG Partners.
TOO TK D HMLP SSW GLOP.PRA GLOP.PRB GLOP GLNG AROC DLNG TGP.PRA TGP.PRB TGP GLOG KNOP DLNG.PRA GMLP DM NS HMLP.PRA

0
Completion of acquisition of equity interest in Golar Hilli LLC

2018-07-12 globenewswire
Golar LNG Partners LP (NASDAQ: GMLP) (the "Partnership") announced today, further to its announcement on August 16, 2017, that it has completed the acquisition of 50% of the common units in Golar Hilli LLC ("Hilli LLC"), the indirect owner of the FLNG Hilli Episeyo. The acquired interest in Hilli LLC represents the equivalent of 50% of the two liquefaction trains, out of a total of four that have been contracted to Perenco Cameroon SA and Société Nationale Des Hydrocarbures pursuant to a Liquefaction Tolling Agreement ("LTA") with an 8 year term, as well as a 5% interest in any future distributions generated by the currently uncontracted expansion capacity of Hilli Episeyo.
GMLP

0
Completion of sale of equity interest in Golar Hilli LLC

2018-07-12 globenewswire
We refer to the press release dated August 16, 2017, which announced the transaction to sell an equity interest in Golar Hilli LLC, the indirect owner of the FLNG Hilli Episeyo, to Golar LNG Partners LP (the "Partnership"). Golar LNG Limited and affiliates of Keppel Shipyard Limited and Black and Veatch have now closed the previously announced sale of 50% of the common units in Golar Hilli LLC to the Partnership with effect from July 12, 2018.
GMLP GLNG

3
GMLP / Golar LNG Partners LP 6-K (Current Report of Foreign Issuer)

2018-07-09 sec.gov
Document Table of Contents UNITED STATES
GMLP

1
GMLP / Golar LNG Partners LP FORM 6-K (Current Report of Foreign Issuer)

2018-07-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EX
GMLP

9
26 'Safer' Dividend 10%+ Yield Stocks Sparkle For July

2018-07-06 seekingalpha
26 of 82 stocks sporting 10%+ yields were tagged as "safer" for dividends because they showed positive 1-year returns and free cash flow yields greater than their dividend yields on 7/3/18.
AIY TCRX AINV SXCP CRIUF AIB ORC TCRD TCRZ TEO VEDL TSLF KIROY KUMBF GMLP CAPL EARN SUN VEDL SNMP

2
Your 82 July 10%+ Dividend Yield Leaders

2018-07-05 seekingalpha
82 stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 7/3/18. Yields above 11.66% narrowed the list to 30 for comparison.
CCR GARS CRIUF VEDL CUSI KIROY PLTYF KUMBF USAC GMLP CAPL OFS SUN VEDL SNMP

0
2018 Annual General Meeting

2018-07-05 globenewswire
Golar LNG Partners LP advises that its 2018 Annual General Meeting will be held on September 26, 2018. The record date for voting at the Annual General Meeting is set to August 1, 2018. The notice, agenda and associated material will be distributed prior to the meeting.
GMLP

11
Just 16 'Safer' Dividend 9%+ Yield Wall St. Stars Blossom For Summer

2018-06-24 seekingalpha
16 of 75 Wall St. favorites sporting 9%+ yields were tagged as "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 6/20/18.
AIY TCRX AINV HMLP SXCP DX AIB ORC TCRD TCRZ TSLF GMLP CAPL SUN DX.PRB DX.PRA HMLP.PRA SNMP

27
Meet 75 June 9%+ Dividend Yield Wall St. Summer Stars

2018-06-22 seekingalpha
75 U.S. stocks displayed 9%+ forward yield, $5+ prices, $100M+ market caps, and .25%+1Yr. targets 6/20/18. Yields above 10.96% narrowed Summer WallStars to 30 for show.
CCR GARS CLA MMLP SMLP DLNG ORC BPL CCLP USAC DLNG.PRA GMLP CAPL CPTA EEP SNMP

9
50 Top Industrial Dividend Yields For June

2018-06-21 seekingalpha
Capital Product Partners led top yielding Industrial target gains with 51.25% calculated by nine analysts, while ANA Holdings was the top stock by yield at 14.96%.
CODI.PRB CPLP HMLP CODI.PRA HOWWF SFL IEP HHILF 0054 HHILY KNOP GMLP ALNPY ALNPF 0737 HMLP.PRA 9202 HOWWY CODI

3
FLNG Hilli Episeyo - Closing of Post Acceptance Debt Financing

2018-06-21 globenewswire
Golar LNG Limited ("Golar" or "The Company") announces today that following the June 4th announcement of commercial acceptance of Hilli Episeyo, the Company has repaid the $640 million drawn under the $700 million construction financing facility and drawn down on the post acceptance $960 million lease financing facility provided by CSSC Leasing. After the closing therefore an additional $320 million of liquidity has been received by Golar.
GMLP GLNG

160
19 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks

2018-06-19 seekingalpha
From 5/15/18-6/15/18, Fredrik Arnold dividend "followers" discussed 36 equities and funds in messages and comments. Some comments were bad news, so rogues created a FollowerFavorite/Rogue (FoFa/Ro) list.
CY WDC ORC CYS.PRA CAPL CLNS.PRDCL CJR.B CYS.PRB AGNC ABBV CLNS APLE CLNS.PRJ CLNS.PRI CLNS.PRH CLNS.PRG CLNS.PRE CLNS.PRD DWDP CLNS.PRB CYS ARR CJREF GMLP JNJ SIR ARR.PRB ABBV ARR.PRA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: Y2745C102